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Background: Vitiligo is a depigmenting skin disease characterised by the appearance of white 
patches due to functional melanocyte loss from the epidermis. It is suggested that autoimmunity is 
involved in vitiligo pathogenesis, as autoantibodies and autoreactive T cells against melanocytes are 
found in vitiligo patients. As part of determining the immunopathomechanisms involved in vitiligo 
development, an important goal is to characterise the specific targets of the immune response. 
Aims: Using phage-display technology, Lamin A was identified as a potential autoantibody target in 
vitiligo. This study aimed to determine how prevalent Lamin A autoantibodies were in vitiligo patients, 
and to find out if there were any associations of Lamin A autoantibodies with demographic or clinical 
features. 
Methods: A radioligand binding assay, using [35S]-labelled Lamin A, was employed to detect Lamin A 
autoantibodies in segmental vitiligo patient (n=8), non-segmental vitiligo patients (n=95) and healthy 
individuals (n=30).  
Results: All healthy controls were negative for Lamin A autoantibodies. 12.5% of segmental vitiligo 
patients and 20% of non-segmental vitiligo patients were positive for Lamin A autoantibodies. A 
statistically significant increase in the prevalence of Lamin A autoantibodies was evident in the vitiligo 
patient group when compared with the healthy controls (P  )LVKHU¶VH[DFWWHVW+RZHYHUWKH
presence of Lamin A autoantibodies was not associated with gender, patient age, disease duration, 
vitiligo onset age, vitiligo activity or the presence of other autoimmune diseases; in comparisons of 
these details in Lamin A autoantibody-positive and autoantibody-negative vitiligo patient groups, all P 
values were > 0.05. 
Conclusions: Overall, the results suggest that Lamin A is an autoantibody target in vitiligo.  
 
